Brain MRI biomarkers for improved follow up of people with Multiple Sclerosis (MS)

Preview:

Citation preview

Brain atrophy!

Lesion !load

TO MEASURE IS TO KNOWBrain MRI biomarkers for

improved follow-up of people with Multiple Sclerosis (MS)

1THE ROLE OF MRI IN MULTIPLE SCLEROSIS

2MRI BIOMARKERS FOR

PEOPLE WITH MS

3GET MRI BIOMARKERS FOR YOUR PATIENTS

1THE ROLE OF MRI IN MULTIPLE SCLEROSIS

Barkhof et al. 2009, Lopez-Diego et al. 2009, Popescu et al. 2013

M U LT I P L ESCLEROSISClassically multiple sclerosis (MS) has been regarded as an auto-immune disease of the white matter in the central nervous system leading to severe disability over the course of several decades. Over the years, substantial evidence emerged that gray matter (GM) is also heavily affected and that neurodegenerative phenomena such as neuronal/axonal damage and GM and White Matter (WM) atrophy play an important role in MS.

CONCEPT OF No Evidence of Disease Activity !

Disease Free Concept

No relapses No disability progression

No T2/Gd lesions

Atrophy within healthy range

CLINICAL

MRI ACTIVITY

Havrdova et al., Roztrousena skleroza, Triton, 2013

THE ROLE OF MRI FOR PEOPLE WITH MS I S GAINING IMPORTANCE

Poser criteria

McDonald criteria2001

McDonald criteria2005

McDonald criteria2010

time

importance

T1, before and after GdIsointensehypointense (black holes)

T2hyperintense

FLAIR hyperintense isointense hypointense

Optional: DIR, DWI

THE BASIC MRI PROTOCOL

T1, before and after GdIsointensehypointense (black holes)

T2hyperintense

FLAIR hyperintense isointense hypointense

Optional: DIR, DWI

THE BASIC MRI PROTOCOL

T1, before and after GdIsointensehypointense (black holes)

T2hyperintense

FLAIR hyperintense isointense hypointense

Optional: DIR, DWI

THE BASIC MRI PROTOCOL

T1, before and after GdIsointensehypointense (black holes)

T2hyperintense

FLAIR hyperintense isointense hypointense

Optional: DIR, DWI

THE BASIC MRI PROTOCOL

HOWEVER, IN CLINICAL PRACTICE,

MRI reports are generally descriptive

No information on brain atrophy or brain volume loss is provided

MRI acquisition is not standardized

THERE IS A NEED FOR RELIABLE MRI MEASURES THAT CAN BE USED IN CLINICAL PRACTICE

2MRI BIOMARKERS FOR

PEOPLE WITH MS

Filippi et al., 2010; Giorgio et al., 2008; Miller et al., 2002; Fisher et al., 2008

0.1 - 0.3% / year

healthy subject

BRAIN VOLUME CHANGES ARE SMALL

0.4 – 1% / year

MS patient

THERE ARE TWO IMPORTANT CONSIDERATIONS FOR USING MRI BIOMARKERS IN CLINICAL PRACTICE

THE MEASUREMENT ERROR SHOULD BE

VERY SMALL

THE MEASURES SHOULD WORK ON

CLINICAL SCANS

Jain et al. NeuroImage Clinical, 2015, Smeets et al. Submitted

MRI measures on clinical data!FLAIR

T1

Lesion segmentation

Tissue segmentation

Jain et al, NeuroImage Clinical, 2015; Lysandropoulos et al, under review, Smeets et al, under review

SMALL MEASUREMENT ERROR!Scan 1, person 1 Scan 2, person 1

PHILIPS

SIEMEN���S

GE

MRI REPORTS WITH INFORMATION ON LESION LOAD AND

BRAIN ATROPHY CAN NOW BE USED

IN ROUTINE CLINICAL PRACTICE

NEURODEGENERATION

INFLAMMATION

VISUAL RESULTS

PATIENT INFO & QC

Survey: are neurologists interested in MRI biomarkers?* !

YES NO ATROPHY LESIONS

ATROPHY+

LESIONS

92%

8%17%

34%

49%

IF YES, WHAT ARE YOU INTERESTED IN?

* Based on 240 responses, survey performed at AAN ‘14, EFNS ‘14, ECTRIMS ’14, AAN’15 !

Survey: would neurologists use MRI biomarkers to help making treatment decisions?* !

YES NO

97%

3%

* Based on 52 responses, survey performed at ECTRIMS ‘14 !

YES NO ATROPHY LESIONS

ATROPHY+

LESIONS

90%

10%18% 21%

61%

IF YES, WHAT ARE YOU INTERESTED IN?

* Based on 126 responses at ECR ‘14 and ECR ‘15 conferences !

Survey: are radiologists interested in MRI biomarkers?* !

3GET MRI BIOMARKERS FOR YOUR PATIENTS

S E N D I N G MRI DATA S E T S I S VERY EASY

CREATE AN ACCOUNT… https://msmetrix.icometrix.com

AND UPLOAD IMAGES https://msmetrix.icometrix.com

Blood lab

icometrix!

IN ADDITION TO RELAPSES, CLINICAL INFORMATION, AND A RADIOLOGICAL REPORT…

…YOU CAN ADD INFORMATION ON LESION

LOAD AND BRAIN ATROPHY

Progression

       

MORE INFORMATION?

ICOMETRIX.COM

wim.vanhecke@icometrix.com

Recommended